CROSSJECT : boosts its US commercial development efforts
(Thomson Reuters ONE) -
CROSSJECT boosts its US commercial development efforts
20 February 2017
CROSSJECT, (ISIN: FR0011716265; Mnemo: ALCJ), a specialty pharma developing a
portfolio of New Therapeutic Entities for emergency auto-injection, is
accelerating the implementation of its strategy for the United States (US).
CROSSJECT has set up several key activities:
* The brokering of Zeneo® Sumatriptan (severe migraines) potential
partnerships for the US and Canada has been entrusted to a London-based
advisory company, operating with a network of seasoned pharma executives
across the US. This network has brokered over 50 pharma business development
deals in the US over the past 10 years, with cumulated upfront payments in
excess of USD 400 million;
* For the regulatory process with the US Food and Drug Administration (FDA),
CROSSJECT has appointed a Washington-based regulatory firm;
* A commercial opportunity assessment for Zeneo® Midazolam (epileptic
seizures) on the US market is being prepared by Bionest Partners, a life-
sciences-focused consulting firm based in New-York and Paris. This type of
assessments are used for business development activities.
Patrick Alexandre, CROSSJECT's founder and CEO, declared: « « In line with our
strategy, we are making sure we can capture the full value of our portfolio of
emergency treatment drugs in the US, and sign the right licensing agreements in
a near future. »
Contacts
CROSSJECT Investor relations
Patrick Alexandre Actifin
info(at)CROSSJECT.com Benjamin Lehari +33 (0)1 56 88 11 25
blehari(at)actifin.fr
Press relations
Citigate Dewe Rogerson
Laurence Bault +33 (0)1 53 32 84 78
laurence.bault(at)citigate.fr
About CROSSJECT · www.CROSSJECT.com
CROSSJECT (ISIN: FR0011716265; Mnemo: ALCJ) is a specialty pharma developing and
conceiving a portfolio of drug candidates for emergency situations (overdoses,
acute migraines, epilepsy, temporary paralysis, anaphylactic chocks, etc.). With
Zeneo®, its patented needle-free injection system, CROSSJECT provides efficiency
to emergency situations by allowing simple drug self-administration.CROSSJECT is
listed on Alternext (Euronext Paris) since February 2014
Follow us on Twitter: (at)Crossject_
Disclaimer
Some of the statements contained in this press release constitute forward-
looking statements. These statements constitute either expectations or goals and
shall not be considered as future results or any other performance indicators.
These statements involve risks and uncertainties, out of control of the company
in certain cases, especially during a R&D process. A detailed description of
these risks and uncertainties is to be found in the Document de Base of the
company, available on its website (www.crossject.com)
CROSSJECT boosts its US commercial development efforts:
http://hugin.info/160011/R/2080232/783322.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: CROSSJECT via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 20.02.2017 - 18:47 Uhr
Sprache: Deutsch
News-ID 525237
Anzahl Zeichen: 3996
contact information:
Town:
Chenôve
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 369 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CROSSJECT : boosts its US commercial development efforts"
steht unter der journalistisch-redaktionellen Verantwortung von
CROSSJECT (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
